Company / CapEx per Share
Theravance Biopharma, Inc. CapEx per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest CapEx per Share
$0.00
FY2025
5-year range
$0.00 / $0.09
FY2021-FY2025
Trend
-87.7%
vs FY2024
Sector context
#174 of 192
Health Care
What the data says
Among 192 Health Care companies, Theravance Biopharma, Inc. is in the bottom 9% for capex per share. CapEx per Share has declined for 3 consecutive years, from $0.09 in FY2022 to $0.00 in FY2025.
Based on SEC 10-K filings.
0.00 in FY2025 with a 5-year CAGR of -62.6%.
Declined from $0.04 to $0.00 over the past 2 years.
Health Care sector context is included.
CapEx per Share over time
Growth rates
- 3-Year CAGR
- -78.8%
- 5-Year CAGR
- -62.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 192This company $0.00 Sector average $3.54
▼
-100.0% below sector average
Key checks
Key Insights
- Theravance Biopharma, Inc.'s capex per share has declined for 3 consecutive years.
- In FY2025, capex per share decreased 87.7% year-over-year.
- Ranks #174 out of 192 companies in the Health Care sector.
- Peak capex per share was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | CapEx per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.00 | -87.7% |
| FY2024 | $0.01 | -81.9% |
| FY2023 | $0.04 | -57.1% |
| FY2022 | $0.09 | +67.9% |
| FY2021 | $0.05 | -54.4% |
| FY2020 | $0.12 | +168.5% |
| FY2019 | $0.04 | +10.1% |
| FY2018 | $0.04 | -13.8% |
| FY2017 | $0.05 | -19.0% |
| FY2016 | $0.06 | -33.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026